Medico Remedies Ltd (BSE: 540937) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹182 Cr, it ranks #2,740 by market cap among the 6,137 Indian listed companies on FinBizNet, and #37 of 63 in Pharmaceuticals. At ₹19.90 (as of 25 Oct 2026), the share price is 63.3% below its 52-week high of ₹54.24 and 4.1% above its 52-week low of ₹19.11. The share price is down 58.5% over one year and down 47.6% over three months.
| Current Price | ₹19.90 |
|---|---|
| Market Cap | ₹182 Cr |
| BSE Code | 540937 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 13.6 |
| Return on Equity | 19.05% |
| Return on Assets | 6.38% |
| 52-Week Range | ₹19.11 – ₹54.24 |
| 1-Year Price Change | -58.5% |
| 3-Month Price Change | -47.6% |
| Beta (1Y) | 0.73 |
| Headquarters | Mumbai, Maharashtra |
| Website | medicoremedies.com |
| Revenue | ₹69 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 3.6% |
| EPS (Basic) | ₹0.30 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.
1. Pharmaceuticals-This segment manufactures and sells pharmaceutical preparations.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Medico Remedies Ltd | ₹182 Cr | 13.6 | 19.05% | ₹69 Cr | -58.5% |
Listed by market capitalisation. Ratios are shown for context only.
Medico Remedies Ltd is trading at ₹19.90, with a market capitalisation of ₹182 Cr.
Medico Remedies Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Medico Remedies Ltd has a P/E of 13.6 and a return on equity of 19.05%.
Medico Remedies Ltd is listed on the BSE under the scrip code 540937.
Medico Remedies Ltd's share price is down 58.5% over one year and down 47.6% over three months. Its 52-week range is ₹19.11 to ₹54.24.
In Q1 FY27, Medico Remedies Ltd reported revenue of ₹69 Cr and net profit of ₹3 Cr, with basic EPS of ₹0.3 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.